Homocysteine and inflammatory biomarkers plasma levels, and severity of acute coronary syndrome

Annales de Biologie Clinique

Volumn 69, Issue 2, 2011, Pages 175-180

  Oudi, Mabrouka El ^a   Bouguerra, Chaker ^a   Aouni, Zied ^a   Mazigh, Chakib ^a   Bellaaj, Ridha ^a   MacHghoul, Salem ^a  

^a MILITARY HOSPITAL OF TUNIS   (Tunisia)

Author keywords

Acute coronary syndrome; Homocysteine; Inflammatory markers; Lipid profile

Indexed keywords

BIOLOGICAL MARKER; HOMOCYSTEINE;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BLOOD; FEMALE; HOSPITALIZATION; HUMAN; INFLAMMATION; MALE; MIDDLE AGED;

ACUTE CORONARY SYNDROME; AGED; BIOLOGICAL MARKERS; FEMALE; HOMOCYSTEINE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 79953841471     PISSN: 00033898     EISSN: 19506112     Source Type: Journal    
DOI: 10.1684/abc.2011.0533     Document Type: Article

References (36)

1. Kinlay S, Selwyn AP, Libby P, Ganz P. Inflammation, the endothelium, and the acute coronary syndromes. J Cardiovasc Pharmacol 1998 ; 32S : 62-6.
2. Zhong-qun Y, Goran KH. Innate immunity, macrophage activation and atherosclerosis. Immunol Rev 2007 ; 219 : 187-203.
3. Saadeddin SM, Habbab MA, Ferns GA. Markers of inflammation and coronary artery disease. Med Sci Monit 2002 ; 8 : 5-12.
4. Poddar R, Sivasubramanian N, Dibello PM, Robinson K, Jacobson D. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: implication for vascular disease. Circulation 2001 ; 103 : 2717-23. (Pubitemid 32538788)
5. Ikeda U. Inflammation and coronary artery disease. Curr Vasc Pharmacol 2003 ; 1 : 65-70.
6. Smith SC, Jackson R, Pearson TA, Fuster V, Yusuf S, Faergeman O, et al. Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the world heart and stroke forum. Circulation 2004 ; 109 : 3112-21.
7. Wang G, Siow YL. Homocysteine induces monocyte chemoattractant protein-1 expression by activating NF-kappa B in THP-1 macrophages. Am J Physiol Heart Circ Physiol 2001 ; 280 : H2840-7.
8. Luton JP2-257-15059-7. Endocrinologie nutrition et maladies métaboliques. Paris : Flammarion, 1999.
9. Preux PM, Dermatt PO, Pema A, Marim B, Vergnenegre A. Logistic regression. Rev Mal Respir 2005 ; 22 : 159-62. (Pubitemid 40476830)
10. Shai I, Stampfer MJ, Ma J, Manson JE, Hankinson SE, Cannuscio C. Homocysteine as a risk factor for coronary heart diseases and its association with inflammatory biomarkers, lipids and dietary factors. Atherosclerosis 2004 ; 177 : 375-8.
11. Hanratty G, Mc Grath LT, Mc Auley DF, Young IS, Johnston GD. The effects of oral methionine and homocysteine on endothelial function. Heart 2001 ; 85 : 326-30. (Pubitemid 32973570)
12. Hsin-Bang L, Chih-Pei L, Wen-Tsai L, Tao-Cheng W, Shing-Jong L, Jaw-Wen C. Circulating mononuclear superoxide production and inflammatory markers for long-term prognosis in patients with cardiac syndrome X. Free Rad Biol Med 2006 ; 40 : 983-91.
13. Martijn van O, Bimmer C, Nick C. Prognostic value of free plasma homocysteine levels in patients hospitalized with acute coronary syndrome. Am J Cardiol 2008 ; 102 : 135-9.
14. Facila L, Nunez JE,VBG. Early determination of homocysteine levels in acute coronary syndromes, is it an independent prognostic factor? Int J Cardiol 2005 ; 100 : 275-9.
15. Su SJ, Huang LW, Pai LS, Liu HW, Chang KL. Homocysteine at pathophysiological concentrations activates human monocyte and induces cytokine expression and inhibits macrophage migration inhibitory factor expression. Nutrition 2005 ; 21 : 994-1002.
16. Pietro EL, Pier LC, Enrico S. Hyperhomocysteinemia, inflammation and autoimmunity. Autoimmunity Rev 2007 ; 6 : 503-9.
17. Holven KB, Aukrust P, Retterstol K. Increased levels of C-reactive protein and interleukin-6 in hyperhomocysteinemic subjects. Scand J Clin Lab Invest 2006 ; 66 : 45-54.
18. Gori AM, Corsi AM, Fedi S. A proinflammatory state is associated with hyperhomocysteinemia in the elderly. Am J Clin Nut 2005 ; 82 : 335-41.
19. Geisel J, Jodden V, Obeid R, Knapp JP, Bodis M, Hermann W. Stimulatory effect of homocysteine on interleukin-8 expression in human endothelial cells. Clin Chem Lab Med 2003 ; 41 : 1045-8. (Pubitemid 37062996)
20. Rus HG, Vlaicu R, Niculescu F. Interleukin-6 and interleukin- 8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 1996 ; 127 : 263-71. (Pubitemid 27045840)
21. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002 ; 105 : 1135-43. (Pubitemid 34212626)
22. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002 ; 347 : 1557-65. (Pubitemid 35315836)
23. Ozdemir O, Gundogdu F, Karakelleoglu S. Comparison of serum levels of inflammatory markers and allelic variant of interleukin-6 in patients with acute coronary syndrome and stable angina pectoris. Coron Artery Dis 2008 ; 19 : 15-9. (Pubitemid 351339961)
24. Arroyo-Espliguero R, Mollichelli N, Avanzas P. Chronic inflammation and increased arterial stiffness in patients with cardiac syndrome X. Eur Heart J 2003 ; 4 : 2006-11. (Pubitemid 37420447)
25. Correia LC, Lima JC, Rocha MS, D'Oliveira Junior A, Pericles Esteves J. Does high-sensitivity C-reactive protein add prognostic value to the TIMI-Risk Score in individuals with non-ST elevation acute coronary syndromes? Clin Chim Acta 2007 ; 375 : 124-8.
26. Friso S, Jacques PF, Wilson PW, Rosenberg IH, Selhub J. Low circulating vitamin B(6) is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels. Circulation 2001 ; 103 : 2788-91. (Pubitemid 32550065)
27. Wouter De R, Rudi GJW, Willem J. Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. BMJ 2008 ; 337 : a3083.
28. Bogdanski P, Pupek-Musialik D, Dytfeld J, Lacinski M, Jablecka A, Jakubowski H. Plasma homocysteine is a determinant of tissue necrosis factor- in hypertensive patients. Biomed Pharmacother 2008 ; 62 : 360-5. (Pubitemid 351899101)
29. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 2003 ; 340 : 115-23.
30. Korhonen T, Savolaienen MJ, Ikaheimo M. Association of lipoprotein cholesterol and triglycerides with the severity of coronary artery disease in men and women. Atherosclerosis 1996 ; 127 : 213-20. (Pubitemid 27046630)
31. La Rosa JC. Understanding risk in hypercholesterolemia. Clin Cardiol 2003 ; 26 : 3-6.
32. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990 ; 82 : 495-506. (Pubitemid 20257828)
33. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989 ; 320 : 915-24. (Pubitemid 19101597)
34. Christa M, Hannelore L,Wilfried M, Wolfgang K. Prognostic value of apolipoprotein B and A-I in the prediction in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/ KORA Augsburg cohort study. Eur Heart J 2005 ; 26 : 271-8.
35. Saeed S, Faramarz F, Mojtaba S, Gholamreza D, Abbasali K,&Tehran Heart Center. Homocysteine, vitamin B12 and folate levels in premature coronary artery disease. BMC Cardiovasc Dis 2006 ; 6 : 38.
36. Erqou S, Kaptoge S. Emerging Risk Factors Collaboration: lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and non vascular mortality. JAMA 2009 ; 302 : 412-23.